ITEMS IN AFP WITH KEYWORD:
Sep 1, 2018 Issue
Blood Pressure Targets for Patients with Hypertension and Cardiovascular Disease [Cochrane for Clinicians]
Achieving a target BP of 135/85 mm Hg or less does not decrease the risk of total cardiovascular events vs. treating to a target of 140 to 160/90 to 100 mm Hg. Further, treating to the lower BP target does not improve total mortality, cardiovascular mortality, or serious adverse effects.
Beginning antihypertensive treatment when the systolic blood pressure is greater than 140 mm Hg delays death and prevents major cardiovascular events in some persons without preexisting heart disease; in patients with existing heart disease, it prevents further events, but does not extend life.
The latest installment of the top 20 research studies for primary care physicians includes studies on cardiovascular disease and hypertension, infections, diabetes mellitus, musculoskeletal problems, and cancer screening, among other topics. The five highest-rated practice guidelines are also summarized.
The American Academy of Pediatrics (AAP) previously published guidance on screening for and managing high blood pressure (BP) in children and adolescents in 2004. An updated guideline was released by the AAP to address increased interest in childhood hypertension (HTN) and an updated search of the literature on the topic.
Mar 15, 2018 Issue
High Blood Pressure: ACC/AHA Releases Updated Guideline [Practice Guidelines]
The American College of Cardiology (ACC) and American Heart Association (AHA) recently updated their guideline on the prevention, detection, evaluation, and treatment of high BP in adults. The ACC/AHA recommendations were based on a systematic review that addressed four questions regarding BP monitoring and treatment for hypertension.
Choosing a threshold and target for treatment should be based on the science supporting CVD risk reduction, while considering the benefits and harms in individual patient circumstances and respecting patient choice.
Feb 1, 2018 Issue
Beta Blockers Compared with Other Drug Options for the Treatment of Hypertension [Medicine by the Numbers]
Although beta blockers seem to have a positive impact on patient-oriented evidence that matters in patients with hypertension, they appear to be inferior when compared with other medications.
Nebivolol/valsartan is an option for the treatment of patients with newly diagnosed or poorly controlled hypertension. Although it offers a new beta-blocker option, no research has demonstrated its benefit over existing treatments.
In this post-hoc analysis of the previously published SPRINT trial, lowering the systolic blood pressure of patients who are at increased risk of cardiovascular events (average age = 66 years) will decrease their risk of cardiovascular disease but increase their likelihood of developing moderate renal dysfunction.
Review common causes of secondary hypertension, including renovascular hypertension, renal disease, primary hyperaldosteronism, and obstructive sleep apnea.